3/10
09:17 am
vcyt
Veracyte (VCYT) Surged on Reporting Strong Earnings [Yahoo! Finance]
Medium
Report
Veracyte (VCYT) Surged on Reporting Strong Earnings [Yahoo! Finance]
3/5
03:11 pm
vcyt
Veracyte Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Low
Report
Veracyte Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
2/27
01:38 pm
vcyt
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom [Yahoo! Finance]
Low
Report
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom [Yahoo! Finance]
2/27
12:08 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Veracyte, Inc. (NASDAQ: VCYT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/25
10:32 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $45.00 price target on the stock.
Medium
Report
Veracyte, Inc. (NASDAQ: VCYT) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $45.00 price target on the stock.
2/25
10:32 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its price target raised by analysts at UBS Group AG from $46.00 to $49.00. They now have a "buy" rating on the stock.
Medium
Report
Veracyte, Inc. (NASDAQ: VCYT) had its price target raised by analysts at UBS Group AG from $46.00 to $49.00. They now have a "buy" rating on the stock.
2/25
10:12 am
vcyt
Veracyte: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Veracyte: Q4 Earnings Snapshot [Yahoo! Finance]
2/25
10:12 am
vcyt
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat [Yahoo! Finance]
Low
Report
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat [Yahoo! Finance]
2/25
08:00 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $51.00 price target on the stock.
High
Report
Veracyte, Inc. (NASDAQ: VCYT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $51.00 price target on the stock.
2/24
08:04 pm
vcyt
Veracyte, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Medium
Report
Veracyte, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
2/24
04:24 pm
vcyt
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/24
04:05 pm
vcyt
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
High
Report
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
2/24
11:23 am
vcyt
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs [Yahoo! Finance]
Low
Report
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs [Yahoo! Finance]
2/22
04:28 pm
vcyt
What To Expect From Veracyte Inc (VCYT) Q4 2024 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Veracyte Inc (VCYT) Q4 2024 Earnings [Yahoo! Finance]
2/21
10:47 am
vcyt
Is Veracyte Stock a Good Addition to Your Portfolio Right Now? [Yahoo! Finance]
Low
Report
Is Veracyte Stock a Good Addition to Your Portfolio Right Now? [Yahoo! Finance]
2/19
05:05 pm
vcyt
Veracyte to Participate in Upcoming Investor Conferences
Low
Report
Veracyte to Participate in Upcoming Investor Conferences
2/18
01:04 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Veracyte, Inc. (NASDAQ: VCYT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/14
08:52 am
vcyt
New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research [Yahoo! Finance]
Medium
Report
New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research [Yahoo! Finance]
2/14
08:30 am
vcyt
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
Medium
Report
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
2/11
09:00 am
vcyt
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium [Yahoo! Finance]
Low
Report
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium [Yahoo! Finance]
2/11
08:30 am
vcyt
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
Low
Report
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
2/10
10:33 pm
vcyt
Veracyte, Inc. (NASDAQ: VCYT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Veracyte, Inc. (NASDAQ: VCYT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
2/5
08:46 am
vcyt
New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer [Yahoo! Finance]
Low
Report
New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer [Yahoo! Finance]
2/5
08:30 am
vcyt
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
Low
Report
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
2/4
04:30 pm
vcyt
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
Medium
Report
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025